[{"orgOrder":0,"company":"Pharmbio Korea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Levodropropizine","moa":"C-fiber sensory nerves","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pharmbio Korea","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmbio Korea \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pharmbio Korea \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Levodropropizina

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmbio Korea

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Pharmbio Korea

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Levodropropizine is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Anemia, Sickle Cell.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 08, 2025

                          Lead Product(s) : Levodropropizine

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank